Indeed, pre-clinical [86–89] and clinical [90] studies show therapeutic efficacy in targeting of AKT or co-targeting AKT and the androgen axis/androgen receptor in castration-recurrent PC, yet ours is the first to use isogenic PC cell lines to address how PTEN and AKT isoform affect metastatic signaling and progression. The gene discussed is AR; the disease is pachyonychia congenita.